REDWOOD CITY, Calif., June 23, 2022 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on delivering treatments using stem cell therapies, has announced today that the company will participate in LifeSci Partners 2n/a Annual Symposium on Genetic Medicines on June 28, 2022.
Ronald Martell, Chief Executive Officer, Jeet Mahal, Chief Operating and Financial Officer, and Wendy Pang MD, Ph.D., Senior Vice President of Research and Translational Medicine, are set to join in a fireside chat Tuesday, June 28e at 4:00 p.m. ET. A live webcast of the presentation will be available on https://wsw.com/webcast/lifesci5/jspr/2165772 and at the company Investor events Web page.
About Jasper Therapeutics
Jasper Therapeutics, Inc. is a biotechnology company focused on developing novel curative therapies based on hematopoietic stem cell biology. The company is advancing two potentially game-changing programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that eliminates hematopoietic stem cells from the bone marrow in patients undergoing hematopoietic cell transplantation. It is designed to enable safer, more effective and potentially curative allogeneic hematopoietic cell transplants and gene therapies. Jasper plans to be a registrational study of JSP191 in AML/MDS patients undergoing allogeneic stem cell transplantation in the first quarter of 2023. A separate clinical study of JSP191 as a new disease-modifying therapy for patients with low-risk MDS is also expected to begin in 2022. Jasper Therapeutics, Inc. is also advancing its preclinical mRNA hematopoietic stem cell transplant platform, which is designed to overcome key limitations of allogeneic and modified autologous stem cell transplants by genes. These two innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to more patients with life-threatening cancers, genetic diseases and autoimmune diseases than ever before. is possible today. For more information, visit us at jaspertherapeutics.com.
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe”, “may”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “should”, “would”, “plan”, “predict”, “potential”, “seem”, “seek”, “future”, “prospect” and similar expressions which predict or indicate future events or trends or which are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the potential of the Company’s mRNA-modified stem cell and JSP191 transplant programs. These statements are based on various assumptions, whether or not identified in this press release, and on Jasper’s current expectations and are not predictions of actual performance. These forward-looking statements are provided for informational purposes only and are not intended to serve as, and should not be relied upon by, any investor as a guarantee, assurance, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from the assumptions. Many real events and circumstances are beyond Jasper’s control. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that potential product candidates developed by Jasper may not progress through clinical development or receive required regulatory approvals on schedule or at all; risks related to uncertainty regarding the regulatory path for Jasper’s product candidates; the risk that the results of previous studies will not be replicated; the risk that clinical trials may not confirm the safety, potency or other product characteristics described or implied in this press release; the risk that Jasper may not be able to successfully commercialize or achieve market acceptance of its product candidates; the risk that Jasper’s product candidates will not benefit patients or be successfully marketed; the willingness of patients to try new therapies and the willingness of physicians to prescribe those therapies; the effects of competition on Jasper’s business; the risk that third parties upon which Jasper depends for laboratory, clinical development, manufacturing and other critical services may not operate satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines and supply chain will be affected by the effects of health outbreaks, including the ongoing COVID-19 pandemic; the risk that Jasper may not be able to obtain and maintain sufficient intellectual property protection for its experimental products or that it will infringe the intellectual property protection of others; and other risks and uncertainties stated from time to time in Jasper’s filings with the SEC. Should any of these risks materialize, or should Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by such forward-looking statements. Although Jasper may choose to update these forward-looking statements at some time in the future, Jasper expressly disclaims any obligation to do so. These forward-looking statements should not be taken to represent Jasper’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed on forward-looking statements.
John Mullaly (investors)
Jeet Mahal (investors)